
Please try another search
By Davit KirakosyanInvesting.com -- Here is your daily Pro Recap of the biggest analyst downgrades you may have missed since yesterday.Marathon Petroleum downgraded at JPMorganJPMorgan downgraded...
Investing.com - Jounce Therapeutics (NASDAQ: JNCE) reported first quarter EPS of $0.990, $1.08 better than the analyst estimate of $-0.090. Revenue for the quarter came in at $82.00M versus the...
(Reuters) - Gilead Sciences (NASDAQ:GILD) will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics (NASDAQ:JNCE) for $67 million, the drugmaker said on...
(Reuters) - Gilead Sciences (NASDAQ:GILD) will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics (NASDAQ:JNCE) for $67 million, the drugmaker said on...
Jounce Therapeutics (JNCE) reported Q3 EPS of ($0.60), $0.02 better than the analyst estimate of ($0.62).
Investing.com - Jounce Therapeutics (NASDAQ:JNCE) reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Jounce Therapeutics announced...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review